BACKGROUND: Blood group single nucleotide polymorphism genotyping probes for a limited range of polymorphisms. This study investigated whether massively parallel sequencing (also known as next-generation sequencing), with a targeted exome strategy, provides an extended blood group genotype and the extent to which massively parallel sequencing correctly genotypes in homologous gene systems, such as RH and MNS.
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BACKGROUND: Blood group single nucleotide polymorphism genotyping probes for a limited range of polymorphisms. This study investigated whether massively parallel sequencing (also known as next-generation sequencing), with a targeted exome strategy, provides an extended blood group genotype and the extent to which massively parallel sequencing correctly genotypes in homologous gene systems, such as RH and MNS.
STUDY DESIGN AND METHODS: Donor samples
(n 5 28) that were extensively phenotyped and genotyped using single nucleotide polymorphism typing, were analyzed using the TruSight One Sequencing Panel and MiSeq platform. Genes for 28 protein-based blood group systems, GATA1, and KLF1 were analyzed. Copy number variation analysis was used to characterize complex structural variants in the GYPC and RH systems.
RESULTS:
The average sequencing depth per target region was 66.2 6 39.8. Each sample harbored on average 43 6 9 variants, of which 10 6 3 were used for genotyping. For the 28 samples, massively parallel sequencing variant sequences correctly matched expected sequences based on single nucleotide polymorphism genotyping data. Copy number variation analysis defined the Rh C/c alleles and complex RHD hybrids. Hybrid RHD*D-CE-D variants were correctly identified, but copy number variation analysis did not confidently distinguish between D and CE exon deletion versus rearrangement.
CONCLUSION:
The targeted exome sequencing strategy employed extended the range of blood group genotypes detected compared with single nucleotide polymorphism typing. This single-test format included detection of complex MNS hybrid cases and, with copy number variation analysis, defined RH hybrid genes along with the RHCE*C allele hitherto difficult to resolve by variant detection. The approach is economical compared with whole-genome sequencing and is suitable for a red blood cell reference laboratory setting.
H uman blood group antigens are of significance in transfusion medicine, because patients who have made antibodies to red blood cell antigens are at risk of being affected by hemolytic transfusion reactions after the transfusion of incompatible blood. The International Society of Blood Transfusion has defined 36 blood group systems and over 350 blood group antigens.
1 Different blood group systems exhibit varying degrees of antigen polymorphism, and the clinical significance of red blood cell antibodies also varies. [2] [3] [4] As a minimum requirement in blood transfusion safety, all blood donors are screened for ABO and the D antigen as well as for blood group antibodies known to be clinically significant. 5 The majority of antigens are missense mutations and a consequence of single nucleotide variants (SNVs); however, genetic variations, such as insertions/deletions and splice-site variants, have a qualitative and/or quantitative impact on antigen expression. Blood group systems, such as RH and MNS, exhibit an additional layer of genetic variation. These arise because each system comprises homologous genes in which gene crossover or gene conversion events have generated complex antigen profiles. For example, in the RH system, crossover between exons for the homologous RHD and RHCE genes can result in RHD*D-CE-D gene variants, generating partial D or D2 phenotypes. In the MNS system, gene conversion between homologous glycophorin B and A (GYPB and GYPA, respectively) can generate GYP(B-A-B) alleles with distinct antigen profiles. 2, 6 Technological advances in this century have led to the development of microarray and matrix-assisted laser desorption/ionization, time-of-flight mass spectrometry (MALDI-TOF MS) DNA typing platforms that detect the SNVs associated with blood group antigens. [7] [8] [9] [10] [11] These systems incorporate SNVs for the most clinically significant antigens and permit automated blood group phenotype predictions based on genotype. 12, 13 However single nucleotide polymorphism (SNP) typing platforms are limited in both the number of blood group systems covered and the range of SNVs targeted within any blood group. 1, 14, 15 The homologous genes, such as RHD and RHCE in the RH system and GYPA and GYPB in the MNS system, pose particular challenges, because a range of rearranged alleles representing RHD/RHCE and GYPB/GYPA hybrids has resulted from gene-rearrangement events. These challenges are managed in part by design of separate SNP genotyping modules, which add to the complexity of blood group test algorithms. Massively parallel sequencing (MPS) or so-called nextgeneration sequencing technologies, have the capacity for extensive and detailed genotyping of novel variants and all known variants and have been used in discovery mode to define new blood group systems and antigens. [15] [16] [17] A few studies have also explored an MPS approach for blood group typing. [18] [19] [20] [21] [22] [23] Lane and colleagues recently provided proof of principle for a whole-genome MPS approach to antigen prediction, showing that a complete and accurate blood group phenotype prediction was obtained for one sample. 24 In this study, we extended the findings of Lane and coworkers 24 by applying a targeted blood group exome MPS approach in a blood service setting. Here, we report that this targeted exome strategy provided extended blood group genotyping and correctly genotyped complex variants in complex gene systems, such as RH and MNS.
MATERIALS AND METHODS

Samples
Our sample group comprised 28 extensively phenotyped and genotyped (by microarray and MALDI-TOF MS) donor samples. Twelve of these samples contributed to blood service reagent red blood cell typing panels (Table  S1 , Samples 1-12; available as supporting information in the online version of this paper). 25, 26 One of these 12 samples (Table S1 , Sample 3) harbored an RHD*CE(3-7)-D rearrangement (RHD*01N.06). Another two samples were hemizygous RHD red blood cell reference samples confirmed by Exon 4 and 7 polymerase chain reaction, 27 which was used for RHD zygosity genotyping (Table S1 
Data analysis
In the chemistry of the TSO assay, individual "barcode" sequences (indices) are added to each sample so that samples can be pooled (multiplexed) before sequencing and reads can be distinguishable for sorting during data analysis. De-multiplexing of indexed reads and the generation of FASTQ files were performed by the MiSeq system on-instrument software. FASTQ files were subsequently imported into the CLC Genomics Workbench software version 8.5 (QIAGEN) and trimmed based on quality using default settings. Trimmed reads were aligned to the human genome reference sequence (hg19/GRCh37). Variant detection was subsequently performed, and an adjusted Illumina manifest file (including only blood group system genes) was used to mask nonblood group-related genes. We applied soft filtering (coverage, 3x; count, 3x; and minimum variant allele frequency, 1%) during secondary data analysis. The CLC Genomics Workbench software was also used to annotate all variants with information on exon numbers, amino acid changes where relevant, and predicted splice-site effect and to annotate known variants from the National Center for Biotechnology Information database (dbSNP human Build 142 and ClinVar archive).
Variant reports were generated from Variant Call Format files exported in Microsoft Excel (spreadsheet) format from CLC Genomics Workbench. We considered coverage, minor variant allele frequency, and strand bias before making a genotype call. The International Society of Blood Transfusion (ISBT) website was our primary resource to manually distinguish variants associated with blood group alleles from the total number of variants present in each sample. 6 For those selected variants associated with blood group alleles, the corresponding phenotype was then predicted using information obtained from the ISBT website. Additional resources included the Blood Group Antigen FactsBook, Human Blood Groups, the Blood Group Antigen Gene Mutation (BGMUT) website, and RHD RhesusBase. 2, 3, 28, 29 In this study, we analyzed 28 of the 33 blood group systems included in the TSO panel for which extensive classification is currently available on the ISBT website. Analysis of the carbohydrate-defined ABO, LE, H, and FORS blood group systems were beyond the scope of this study. The CH/RG blood group system was also excluded from analysis, because no allele information was available on the ISBT website. In addition to the 28 blood group systems, we also analyzed genes for the transcription factors KLF1 (Kruppel like factor 1) and GATA1 (GATA binding protein 1). 6 For the P1PK system, the TSO panel does not include a 1,4-galactosyltransferase (A4GALT) Exon 2a as a target and thus could not be used to identify the nucleotides associated with P1 expression. Table 1 lists the blood group systems and associated genes included in the data analyses and indicates the genes for which sample data were available from SNP genotyping platforms. 25 Red blood cell antigen predictions were based on genotyping calls made after manual analysis of variant reports. For those blood group system-related genes in which no variants were detected for a given sample, the genotype was assumed to be the same as the reference sequence, and the phenotype was predicted as such. The genotypes of reference genes referred to in the ISBT Blood Group Allele Tables or BGMUT do not always correspond with genotypes for hg19/GRCh37. To ease the bioinformatics process, the blood group genotypes and corresponding phenotypes for hg19/GRCh37 were identified at the outset. A comprehensive report on these discrepancies and on red blood cell antigen prediction for hg19/GRCh37 was recently published by Lane and colleagues. 24 Manual prediction of phenotype from variant calls was also performed by an additional operator who was blinded to the blood phenotypes present in the sample cohort. We also considered results from copy number variation (CNV) analysis for phenotyping/genotyping for the RH (RHD and RHCE) and GE (GYPC) blood group systems, because both systems have several alleles that are defined by exonic rearrangements or deletions/duplications/triplications. Our CNV approach followed methods described in a recent report by Feng and coworkers. 30 
RESULTS
TSO performance: coverage and specificity
Illumina guarantees that 95% of targets will be covered at 20x minimum coverage. Our average sequencing depth per target region was 66.2 6 39.8. The mean sequencing depth using the MiSeq is considerably lower than the mean sequencing depth of 874 to 1475x reported by Feng and colleagues using the HiSeq2000 (Illumina) but still allowed for CNV analysis. 30 For sequencing runs with optimum cluster density (1000-1200 K/mm 2 ), 92.8% of targets had an average sequencing depth greater than or equal to 20x, and only one target (erythroblast membraneassociated protein [ERMAP] Exon 5) had an average sequencing depth less than 1x. Runs with suboptimal cluster density (due to under clustering) still enabled accurate genotyping to give phenotype predictions. 
Evaluation and optimization of parameters for SNV detection
The parameters evaluated during variant detection included quality score (QS), minimum coverage, and minimum variant allele frequency. Sequencing QS provides a measure of the probability that a base is called incorrectly. For example, a QS of 30 for a base call represents an error rate of 1 in 1000 or 99.9% accuracy. For all of the 28 samples, all the detected SNVs used for genotyping had a QS of 30 or greater.
Minimum coverage refers to the minimum number of valid reads needed to align to a known reference base in order to derive a base call for inclusion in the variant report. All variant reports contained some variants with sequencing coverage less than 20x. The minimum coverage for variants ranged from 3x to 12x, and the maximum ranged from 50x to 304x. For nine validation samples, filtering to exclude variants with sequencing coverage less than 20x would have led to wrong phenotype prediction for M or N. For these samples, the sequencing coverage for GYPA ranged from 5x to 16x and from 10x to 19x for nucleotide positions corresponding to amino acid substitutions at positions 20 and 24, respectively. 2 The minimum variant allele frequency is the minimum fraction of DNA sequence reads, which contain the variant allele rather than the reference/germline allele, needed to cover the variant position in order to be considered heterozygous and to be included in the variant report. The minimum allele frequencies for heterozygous variants across all samples, on average, were 21.7% (95% confidence interval, 15.9-29.4). Only four samples contained some (range, 6-13) variants with an allele frequency below 15.9%. None of these low-frequency allele variants were considered during phenotype predictions.
Variant detection and correlation with SNP typing results
Variant reports contained a total of 43 (69) variants on average for each sample in the genes related to the 28 blood group systems and 2 transcription factors analyzed. Of this total number of variants, an average of 16 (64) lead to synonymous amino acids, 25 (67) lead to nonsynonymous amino acids, and 2 (61) are situated in intronic positions. On average, 6 (66) variants were not annotated with a reference SNP cluster identifier (rs number). The lack of an SNP cluster ID could be indicative of the SNP track version used, a novel variant, or a false-positive call (background noise).
Of the total number of SNVs contained in each variant report, an average of 10 (63) SNVs were used to provide genotype calls for the 28 blood group systems, GATA1, and KLF1. For the 28 samples, MPS variant sequences correctly matched the expected sequence based on SNP genotyping data. For all samples, MPS enabled more extensive genotyping by providing data on blood group systems that were not included on SNP typing panels. Table S1 presents the observed serological phenotype for all 28 samples and compares it with the MPS-defined genotype and the MPSpredicted phenotype.
We also obtained 100% concordance for phenotype calls by MPS compared with SNVs identified for four samples (Table S1 , Samples 15-18) with the DEL, partial, weak D, or D2 phenotypes. Three of the four samples harbored the following variants, respectively: c.148 1 1G > A (RHD*DEL5; DEL phenotype), c.329T > C (RHD*DVII.01; partial phenotype), and c.343delC (RHD*01N.23; negative phenotype). For the fourth sample, with a weak D phenotype, the RHD gene was present in two copies as well as two variants (c.329T > C and c.809T > G), defining the RHD*DVII.01 and RHD*weak D type 1 alleles, each at the heterozygous level. We were unable to specify whether these respective SNVs were on the same or different haplotypes. However, the weak D phenotype of this sample suggested that each variant occurred on a different RHD gene.
The TSO panel does not target GYPB Pseudoexon 3 specifically but is designed to target the homologous GYPA Exon 3 sequence. The four hybrid GYP(B-A-B) samples tested (Table S1 , Samples 24-27) were represented by GYP*Mur homozygote, GYP*Mur heterozygote, GYP*Hop heterozygote, and GYP*HF heterozygote alleles. 6, 11 For these hybrids, composite sequence reads containing both GYPB and GYPA variants aligned to GYPB Pseudoexon 3 and to GYPA Exon 3. Different GYP(B-A-B) hybrids were detected and distinguished by identifying the insertion of GYPA Exon 3 sequences into the GYPB Pseudoexon 3 through variant detection in GYPB Pseudoexon 3. Sequence reads for GYP*-Mur homozygous, GYP*Mur heterozygous, GYP*Hop heterozygous, and GYP*HF heterozygous matched the expected nucleotide sequences. Figures 2 and 3 illustrate the respective reference alignment of reads for the homozygous GYP*Mur sample (Table S1 , Sample 24) against GYPB Pseudoexon 3 and GYPA Exon 3. The sequence reads for GYPA (Fig. 3 ) are enriched compared with those for GYPB (Fig. 2) , because the target design was specific for GYPA. In summary, MPS genotyping showed 100% concordance with the expected SNVs for the four hybrids tested.
CNV analysis-RHD and RHCE
The RH blood group system is encoded by the homologous genes RHD and RHCE; therefore, we considered these two genes together. We set normalized mean coverage ratio cutoff values for heterozygous deletions between 0.2 and 0.75 and for duplications above 1.5 as determined by statistical analysis.
Identification of RHD (RHD*01) and a homozygous or hemizygous RHD gene deletion (RHD*01N.01)
Manual interpretation of results for CNV analysis enabled us to identify the presence of homozygous normal RHD (RHD*01) and hemizygosity or homozygosity for an RHD gene deletion (RHD*01N.01). At the same time, we identified the presence of c.307C > T (one of the SNVs defining the RHCE*C allele) at a homozygous or heterozygous level.
The clustered column chart in Fig. 4A shows that, for a homozygous RHD*01 sample (Table S1 , Sample 10), the normalized mean coverage ratio for all RHD exons (blue), except Exon 8, are above the cutoff value of 0.75, indicating the presence of two RHD copies. The nucleotide sequences of Exon 8 for RHD and RHCE are identical; and, for all samples, the CLC Genomic Workbench software consistently aligned the vast majority of Exon 8 reads to RHCE. In Fig. 4A , this trend can be seen in the almost double than expected increase in the ratio for RHCE Exon 8 (red). Having identified this limitation in the sequencing panel, we find that mappings to Exon 8 for the RH gene cluster are uninformative.
The nucleotide sequence of Exon 2 for an RHCE*C allele is identical to that of RHD Exon 2. 24 The CLC Genomic Workbench software consistently aligns almost all reads for RHCE*C Exon 2 to RHD Exon 2. We exploited this to identify the presence of an RHCE*C allele. The presence of a homozygous RHCE*C allele can be seen in Fig. 4A , in which the normalized mean coverage ratio for RHCE Exon 2 is less than 0.2 and that of RHD Exon 2 is greater than 1.5, indicating that almost all of the reads belonging to RHCE Exon 2 aligned to RHD Exon 2. The charts in Fig. 4B ,C represent homozygous RHD*01N.01 (D2 phenotype) samples (Table S1 , Samples 8 and 2). For both samples, the ratios for almost all RHD exons are less than 0.2, indicating a homozygous RHD gene deletion. For the sample in Fig. 4B , all of the reads aligned to RHD Exon 2 belong to RHCE*C Exon 2. This led to a ratio of 60.5 for both RHD and RHCE Exon 2, which indicates the presence of a heterozygous RHCE*C allele. The sample represented in Fig. 4C is homozygous for the RHCE*c allele, as indicated by a ratio of less than 0.2 for RHD Exon 2 compared with a ratio of 61 for RHCE Exon 2. In seven of 12 samples with normal RHD, hemizygous RHD, and homozygous RHD gene deletions (e.g., Fig. 4B,C) , some RHCE Exon 1 reads aligned incorrectly to RHD Exon 1. The ratios observed for Exon 1 in these cases could be misleading; however, with this in mind, we were still able to correctly identify RHD*01, RHD*01N.01, and RHCE*C. We could not identify any pattern (e.g., the presence of c.122A > G [RHCE*CeCW]) that would explain misalignment of reads for RHCE Exon 1.
The clustered column chart in Fig. 4D shows that, for a hemizygous RHD sample (Table S1 , Sample 13), the normalized mean coverage ratio for all RHD exons (blue), except Exons 1 and 8, are between 0.2 and 0.75, indicating the presence of only one RHD copy. The previously discussed misalignment of reads for Exons 1 and 8 by the CLC Genomic Workbench software were considered before providing a genotype call.
Identification of RH gene rearrangements
We manually identified the possible presence of an RH gene rearrangement in six samples harboring hybrid RHD*D-CE-D alleles from CNV analysis results. These samples (Table S1, The clustered column charts in Fig. 5A -F show six samples that are hemizygous for RHD and harbor an RH gene rearrangement in the single RHD copy present. For all six samples, the complete absence of reads for certain RHD exons (blue) can be seen where ratios are less than 0.2. The RHD hemizygosity for these samples is evident where the ratios for the remaining RHD exons are between 0.2 and 0.75 (allowing for the minor variations observed for Exons 1 and 2, as discussed above). Although an accompanying increase (>1.49) in the ratios for RHCE exons involved in the rearrangement would be expected, this was not consistently observed. Therefore, when making a genotype call, we indicated the presence of either an RH rearrangement or an RHD exon(s) deletion.
As discussed above, the sequence of Exon 8 is identical for RHD and RHCE; therefore, we were unable to specify whether or not Exon 8 was part of a gene rearrangement. The presence of an RHCE*C allele can be identified in Samples 5A through 5E based on the decreased ratio (from 0.2 to 0.75) for RHCE Exon 2 and the accompanying increase in the ratio for RHD Exon 2 (from 60.75 to 1.0). Therefore, when considering the impact of the presence of an RHCE*C allele, the true ratio for RHD Exon 2 for Samples 5A through 5E should be between 0.2 and 0.75, consistent with RHD hemizygosity for these samples. BLOODchip Reference Analysis (Progenika, Inc.) results for Sample 5B (Table S1 , Sample 19) indicated the presence of RHD*CE(2-7)-D (RHD*01N.05). MPS defined an RHD*CE(3-7)-D (RHD*01N.06) rearrangement for this sample, because CNV analysis could not clearly define whether or not Exon 2 is involved. The phenotypic prediction for this sample remains the same, however: that is D2. For this reason, the profile for Sample 5B is the same as that for Sample 5A in Fig. 5 .
Sample 5F does not harbor c.307C > T associated with the RHCE*C allele. However, the variant analysis defined the presence of the changes on the RHCE*c allele associated with the weak C1 phenotype referred to as C 1 W . Therefore, the CNV analysis, combined with the variant detection data, defined the hybrid D haplotype r' S type 1, which is associated with the C 1 W phenotype. The RHD*DIII.04-ceVS.03(4-7)-D phenotype of Sample 5F results in a reduction in the RHD Exon 3 mapping ratio compared with Exons 9 and 10, because the 5 0 end of this exon is comprised of RHD sequence, whereas the 3 0 end of this RHD exon is comprised of RHCE sequence. As mentioned above, the CLC Genomics Workbench software has a tendency to align some RHCE Exon 1 reads to RHD Exon 1. This trend can be seen in all six samples and was considered during manual interpretation.
Accuracy of RH phenotype predictions
We calculated the sensitivity, specificity, positive predictive value, and negative predictive value by evaluating phenotypic calls for all exons for RHD and RHCE in each sample. In doing this, we recognize that the trends in alignment of sequence reads for Exons 1 and 8 will lower the calculated sensitivity and specificity. Data used as comparison against MPS phenotype predictions consisted of the consensus phenotypes when considering all available serology and SNP typing results. The sensitivity for the detection of a deletion in RHD and RHCE using the CNV approach is 89.8% and, for duplications, 52.8%. The specificity for the detection of a deletion was 92.4% and, for duplications, 94.8%. The false-positive rate for deletions and duplications were similar (7.6 and 5.2%, respectively), which is a dramatic improvement in the previously reported rates (75.61 and 96.77%, respectively). 30 The negative predictive values for deletions and duplications were similar (95.4 and 94.1%, respectively), but the positive predictive value for deletions was higher (83.8%) than for duplications (55.9%). Decreased performances for the detection of duplications were also reported previously for whole-exome sequencing and means that one cannot say for certain whether an RHCE sequence is inserted or the RHD sequence is deleted. 30, 31 The sensitivity and specificity for detecting the RHCE Exon 2 deletion and accompanying RHD Exon 2 duplication indicative of RHCE*C is 100%.
CNV analysis-GYPC
The Gerbich blood group system consists of 11 alleles, of which four are defined by exon deletions/duplication/ triplication. These alleles are rare in most populations, and only one Gerbich type example was included in our validation sample panel. The allele (GE*01.203) is defined by a deletion in GYPC Exon 3 that causes an in-frame deletion. The ratios of 1.26, 0.5, and 0 were applied as cutoff values to represent two copies, one copy, and the absence of GYPC exons, respectively. We identified the absence of GYPC Exon 3 in our example of a Gerbich type sample as indicated by a ratio equal to zero for Exon 3 (Fig. 6) . In Fig. 6 , GE*01 was used as test control.
DISCUSSION
This study evaluated a targeted MPS approach to provide an extensive blood group genotype profile for a panel of characterized samples. The approach employed a commercial targeted exome sequencing panel that sequences coding DNA, flanking splice sites, and untranslated regions. Our study analyses were restricted to 28 proteinbased blood group systems; and, for all samples, our predictions matched previously determined blood group phenotypes. Accurate calls were also provided for the homologous gene systems. We showed that CNV analysis for RH could accurately determine RHD zygosity and the presence of the c.307C > T variant (RHCE*C), which hitherto has been problematic with MPS technologies. 24 Lane and colleagues recently showed proof of principle for a whole-genome sequencing approach to blood group genotyping. 24 Other research groups have devel- product pools; one containing RHD and GYPA Exons 1 and 2 and the other containing RHCE and GYPB Exons 1 and 2. Our approach permitted the targeting of more blood group systems than previously reported for other MPS custom sequencing panels and is performed in a single test. [18] [19] [20] [21] [22] For each of the 28 samples tested in this study, the TSO system revealed SNVs that were not informative for blood group genotyping, particularly for some single-gene blood group systems. Interestingly, these were not observed for exonic regions of the highly polymorphic RH system.
2 Future studies will enable further classification of these variants according to significance. For example, some variants may be population and/or haplotype associated, and some may affect phenotypic expression. There were limitations inherent in the study design, sequencing panel, and bioinformatics. For the study design, we selected samples that had predefined phenotype and SNP genotyping data available. To overcome this, samples were de-identified on the sequencing run, and data analysis Normalized mean coverage ratios are presented on the y-axis. A ratio above 1.5 corresponds to a 50% or more increase in mean read depth, a ratio between 0.2 and 0.75 correspond to a 50% decrease in mean read depth, and a ratio of less than 0.2 corresponds to a 100% decrease in mean read depth. At the top of each chart, the genotype is indicated in black, and the corresponding phenotype is indicated in gray. (A-F) Results for six hemizygous RHD samples harboring RHD/RHCE rearrangements (Table S1 , Samples 3 and 19-23). Samples A through E also harbor a heterozygous RHCE*C allele. The limitations of the panel result in uninformative mappings to Exons 1 and 8, and these are not included in the interpretation of the data.
was performed by two operators. Predictions by both operators matched those obtained by SNP genotyping for all samples, which accurately reflected the phenotype.
For the sequencing panel, three blood group systems are not covered, and coverage for P1 is limited. For the homologous RH gene system, an additional intronic sequence flanking Exon 8 would be required to discriminate between RHD and CE. The short fragment size does not enable haplotype phasing where the gene is present in two copy numbers and two or more variants are detected, unless the variants are within a read length distance. This was exemplified by one sample that was heterozygous for SNPs associated with both partial and weak D types. For CNV analysis of complex RHD genes, although the sensitivity and specificity for identifying RHD exon absences were high, we were unable to discriminate between a deletion and a rearrangement with RHCE with confidence in all cases. Where encountered, these limitations would necessitate incorporating allele-specific, long-range PCR approaches into the test algorithms.
Despite these limitations, the targeted exome approach, in principle, is more economical than a wholegenome approach for blood group typing, and the apparent limitations in the number and length of RBC exome targets could be addressed with a custom-designed panel and longer read chemistry. For the homologous gene systems, the approach correctly identified GYP(B-A-B) hybrid sequences and the lack of RHD sequences for a selection of complex samples with RHD*D-CE-D rearrangements.
Finally, the bioinformatics analysis was manual, although it was possible and dependent on the information from well-curated public international databases. Unsuitable data file formats and a lack of key pieces of information (e.g., SNP cluster identification and chromosomal coordinates) prohibited full automation of the bioinformatics process. Developments in the prediction algorithms capable of automated phenotype prediction from MPS data have been reported. 24, 32 Increased automation of the bioinformatics process would increase the viability of genotyping by MPS for extended blood group typing of donors and patients. However, the current study shows the potential to apply the technology in a red blood cell reference laboratory setting.
In conclusion, this study provides proof of principle that targeted exome MPS genotyping for SNV detection and additional targeted CNV analysis is a valid approach to extend blood group genotyping. It allowed phenotype predictions for an increased number of antigens and blood group systems compared with SNP typing panels and enabled accurate identification of known variants not targeted by current SNP typing platforms. 
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